Neurelis has announced the launch of Valtoco diazepam nasal spray for the treatment of seizure clusters in the US. The FDA approved Valtoco for the treatment of acute repetitive seizures in epilepsy patients aged 6 and older in January 2020. According to the company, patients can now obtain Valtoco through Maxor Specialty Pharmacy, which has already started filling prescriptions.
Neurelis President and CEO Craig Chambliss commented, “We understand the high unmet need for Valtoco and we are very pleased to be able to make this available for patients with seizure clusters less than two months after our FDA approval. Our commitment to the epilepsy community drives every team member at Neurelis as we accomplish this goal.”
Chief Commercial Officer Chuck DeWildt said, “Valtoco is the first commercial product for Neurelis and we are now rapidly building our commercial organization. Working with Maxor allows us to expedite the availability of Valtoco for patients, healthcare providers and care partners who need it in advance of Valtoco availability in retail pharmacies in the near future.”
Read the Neurelis press release.
